Loading organizations...
§ Venture Capital · Shanghai, China
Lichen Capital is an investment firm.
Lichen Capital operates as an investment firm with a strategic focus on equity investment, mergers and acquisitions, and providing guidance for companies pursuing domestic and overseas IPO listings. The firm leverages its experience to support businesses through various growth stages, demonstrating a particular interest in sectors such as biopharma and healthcare. Its investment activities include participating in funding rounds for emerging companies, often alongside other institutional investors, to facilitate their development and market expansion. This comprehensive approach positions Lichen Capital as a partner for businesses seeking both capital and strategic market entry expertise, aiming to foster growth and achieve successful market outcomes.
Lichen Capital provides services such as domestic and overseas IPO listing guidance and mergers and acquisitions, in addition to its equity investment activities.
Lichen Capital has invested in companies within the biopharma and healthcare sectors, including firms like Biopharma Bivision, Agile Medical, and Spurious.
Lichen Capital provides services such as domestic and overseas IPO listing guidance and mergers and acquisitions, in addition to its equity investment activities.
Lichen Capital has invested in companies within the biopharma and healthcare sectors, including firms like Biopharma Bivision, Agile Medical, and Spurious.
Lichen Capital operates as an investment firm with a multifaceted approach, encompassing equity investment, mergers and acquisitions, and specialized guidance for companies pursuing domestic and overseas IPO listings. The firm aims to support businesses through critical growth phases by providing both capital and strategic advisory services. Its operational model is designed to facilitate corporate development and market entry for its portfolio companies.
The firm has built an investment portfolio that includes at least 11 distinct investments. These investments span various industries, with a notable presence in the life sciences. For instance, Lichen Capital participated in the angel funding round for Biopharma Bivision, a company in the biopharmaceutical sector. Another recorded investment includes Agile Medical, indicating a focus on the broader medical field. Furthermore, the firm has supported healthcare entities such as Spurious, contributing to its seed funding round.
Lichen Capital frequently engages in co-investment strategies, partnering with other capital providers to syndicate funding rounds. This collaborative approach is evident in its investment history; for the Biopharma Bivision round, it invested alongside Kaitai Capital. Similarly, in the seed round for Spurious, Lichen Capital was part of a syndicate that included BioTrack Capital, Hankang Capital, and LongRiver Investments, demonstrating its capacity to work within broader investment consortia.
The firm's involvement in diverse funding rounds, from early-stage angel and seed investments to later-stage equity participation, underscores its role in the capital formation landscape. By combining direct investment with strategic M&A and public market preparation services, Lichen Capital positions itself as a comprehensive financial partner. Its activities are geared towards identifying and nurturing companies with high growth potential, guiding them towards successful market outcomes and expansion.
Lichen Capital has 1 tracked investment across 1 company. The latest tracked deal is $35.0M Seed in Spurious in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 30, 2026 | Spurious | $35.0M Seed | Highlight Capital | Biotrack Capital, Hankang Capital, InnoPinnacle Fund, LongRiver Investments |